External Counterpulsation (ECP) is a simple, non-invasive, non-pharmacological, low risk, painless therapy to treat coronary artery disease. The US Food and Drug Administration (FDA) approved Model US-ECP (510(k) #030587).
Patients who are candidates for ECP treatment normally undergo 35 hours of therapy - treatment is 1-2 hours a day, five days a week, for 7 weeks. Treatments are covered by Medicare and most health insurance plans.
a) Transfer of US Food and Drug Administration (FDA) 510(k) K030587 and K030587/A001 for External Counterpulsation Model US-ECP.
b) Four (4) Model US-ECP systems and all available spare parts.
c) All available circuit diagrams related to External Counterpulsation Model US-ECP.
d) All available information related to the software operating system for External Counterpulsation Model US-ECP.
e) All available technical information related to the manufacture, operation and maintenance of External Counterpulsation Model US-ECP.
f) Transfer of website www.usecp.com and all DVD media assets.
g) Transfer of domain name and internet service.